- Home
- BRT vs RXST Comparison
BRT vs RXST Comparison
Compare BRT & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRT | RXST |
|---|---|---|
| Founded | 1972 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.0M | 208.8M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRT | RXST |
|---|---|---|
| Price | $13.11 | $4.90 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 10 |
| Target Price | ★ $17.50 | $6.10 |
| AVG Volume (30 Days) | 51.5K | ★ 810.1K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | ★ 7.96% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $1.10 | $9.02 |
| Revenue Next Year | $7.98 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $12.51 | $4.11 |
| 52 Week High | $15.63 | $13.22 |
Technical Indicators
Market Signals| Indicator | BRT | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 49.55 |
| Support Level | N/A | $4.55 |
| Resistance Level | $14.99 | $4.98 |
| Average True Range (ATR) | 0.45 | 0.34 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.82 | 56.55 |
Price Performance
Historical ComparisonAbout BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture, and sale of light adjustable lenses and related capital equipment.